TABLE 4.
Top 15 RCT of anti-PD1/PDL1 sorted by LCS.
| Title | Source | Year | LCS | GCS |
|---|---|---|---|---|
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | HERBST RS, LANCET | 2016 | 37 | 2,399 |
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial | RITTMEYER A, LANCET | 2017 | 27 | 1,426 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial | FEHRENBACHER L, LANCET | 2016 | 18 | 1,151 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | WEBER JS, LANCET ONCOL | 2015 | 13 | 1,331 |
| Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-years overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial | HODI FS, LANCET ONCOL | 2016 | 11 | 392 |
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | KANG YK, LANCET | 2017 | 11 | 431 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | RIBAS A, LANCET ONCOL | 2015 | 9 | 791 |
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study | LANGER CJ, LANCET ONCOL | 2016 | 8 | 633 |
| Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial | BRAHMER JR, LANCET ONCOL | 2017 | 7 | 81 |
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized phase II Trial | MOTZER RJ, J CLIN ONCOL | 2015 | 6 | 556 |
| Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial | CELLA D, LANCET ONCOL | 2016 | 6 | 106 |
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | SCHACHTER J, LANCET | 2017 | 5 | 331 |
| Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-years outcomes of a multicentre, randomised, phase 3 trial | HODI FS, LANCET ONCOL | 2018 | 5 | 230 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | MCDERMOTT DF, NAT MED | 2018 | 5 | 169 |
| Nivolumab vs. investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-years long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | FERRIS RL, ORAL ONCOL | 2018 | 5 | 108 |